Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome

Current Opinion in Rheumatology

Volumn 21, Issue 5, 2009, Pages 443-447

  Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Endosome recycling; Glutathione; Interferon; Lupus; Lysosome; Mammalian target of rapamycin; Nitric oxide; Nuclear factor kappa B; Oxidative stress; Sjogren's syndrome

Indexed keywords

ABATACEPT; ACETYLCYSTEINE; ALPHA INTERFERON; ATACICEPT; ATLIZUMAB; BELIMUMAB; BORTEZOMIB; DNA ANTIBODY; EPRATUZUMAB; GLUTATHIONE TRANSFERASE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MAMMALIAN TARGET OF RAPAMYCIN; NITRIC OXIDE; PROTEASOME; PROTEIN TYROSINE KINASE; RAPAMYCIN; STAT4 PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL INTERACTION; CLINICAL TRIAL; DRUG TARGETING; ENDOSOME; GENE IDENTIFICATION; HUMAN; LYSOSOME; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; RETROVIRUS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

EID: 69549092428     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832efe6b     Document Type: Review

References (68)

1. Perl A. Pathogenesis and spectrum of autoimmunity. In: Perl A, editor. Autoimmunity. Methods and protocols, ed. 1 Totowa, New Jersey: Humana Press; 2004. pp. 1-8.
2. Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2005; 17:518-522. (Pubitemid 41527809)
3. Fox RI. Sjogren's syndrome: immunobiology of exocrine gland dysfunction [review]. Adv Dent Res 1996; 10:35-40.
4. Steinberg AD, Gourley MF, Klinman DM, et al. Systemic lupus erythematosus. Ann Intern Med 1991; 115:548-559.
5. Harley JB, Moser KL,Gaffney PM, Behrens TW. Thegenetics of humansystemic lupus erythematosus [review]. Curr Op Immunol 1998; 10:690-696.
6. Arnett FC, Reveille JD. Genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 1992; 18:865-892.
7. Perl A. Mechanisms of viral pathogenesis in rheumatic diseases (invited review). Ann Rheum Dis 1999; 58:454-461.
8. Harley JB, Harley IT, Guthridge JM, James JA. The curiously suspicious: a role for Epstein-Barr virus in lupus [review]. Lupus 2006; 15:768-777.
9. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40:204-210.
10. Kyttaris VC, Krishnan S, Tsokos GC. Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity 2006; 39:705-709. (Pubitemid 44964373)
11. Scofield RH. Genetics of systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol (in press).
12. Jacob CO, Zhu J, Armstrong DL, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A 2009; 106:6256-6261. An original article documenting a genetic role as well as a mechanistic role for IRAK1 in lupus.
13. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134:587-598. An original article documenting the role of TREX1 in controlling a cell-intrinsic IFN response, revealing a novel mechanism of autoimmune pathogenesis due to the activation of endogenous retroviral elements.
14. Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007; 39:1065-1067.
15. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357:977-986. (Pubitemid 47367077)
16. Sigurdsson S, Nordmark G, Göring HHH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76:528-537. (Pubitemid 40250533)
17. Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76:561-571.
18. Rieck M, Arechiga A, Onengut-Gumuscu S, et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-4710.
19. Kozyrev SV, Abelson AK, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008; 40:211-216. An original article, documenting the genetic association of a B-cell activationrelated gene, B-cell scaffold protein with ankyrin repeats 1 (BANK1), in SLE. (Pubitemid 351171404)
20. Pullmann R Jr, Bonilla E, Phillips PE, et al. Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum 2008; 58:532-540. (Pubitemid 351294887)
21. Fernandez DR, Telarico T, Bonilla E, et al. Activation of mTOR controls the loss of TCR in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009; 182:2063-2073. An original article documenting the activation of the mTOR by nitric oxide in lupus T cells that promotes the lysosomal degradation of TCRζ via stimulating expression of HRES-1/Rab4.
22. Vyshkina T, Sylvester A, Sadiq S, et al. Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin Immunol 2008; 129:31-35.
23. Perl A, Banki K. Human endogenous retroviral elements and autoimmunity: data and concepts. Trends Microbiol 1993; 1:153-156. (Pubitemid 23187185)
24. Perl A. Endogenous retroviruses in pathogenesis of autoimmunity [editorial]. J Rheumatol 2001; 28:461-464. (Pubitemid 32202642)
25. Perl A. Role of endogenous retroviruses in autoimmune diseases [review]. Rheum Dis Clin North Am 2003; 29:123-143. (Pubitemid 36298107)
26. Perl A, Nagy G, Koncz A, et al. Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity 2008; 41:287-297. (Pubitemid 351593859)
27. Magistrelli C, Banki K, Ferrante P, Perl A. Mapping and cloning of polymorphic genotypes of the HRES-1 LTR. Arthritis Rheum 1994; 37:S316.
28. Magistrelli C, Samoilova E, Agarwal RK, et al. Polymorphic genotypes of the HRES-1 human endogenous retrovirus locus correlate with systemic lupus erythematosus and autoreactivity. Immunogenetics 1999; 49:829-834. (Pubitemid 29381443)
29. Nagy G, Ward J, Mosser DD, et al. Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem 2006; 281:34574-34591. (Pubitemid 46036664)
30. Kyttaris VC, Tsokos GC. T lymphocytes in systemic lupus erythematosus: an update [review]. Curr Opin Rheumatol 2004; 16:548-552. (Pubitemid 39128322)
31. Tsao BP, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997; 99:725-731.
32. Gaffney PM, Kearns GM, Shark KB, et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc Natl Acad Sci U S A 1998; 95:14875-14879.
33. Moser KL, Neas BR, Salmon JE, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci U S A 1998; 95:14869-14874.
34. Tsao BP, Cantor RM, Grossman JM, et al. PARP alleles with the linked chromosomal region are associated with systemic lupus erythematosus. J Clin Invest 1999; 103:1135-1140.
35. Shai R, Quismorio FP Jr, Li L, et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 1999; 8:639-644. (Pubitemid 29139978)
36. Abelson AK, Delgado-Vega AM, Kozyrev SV, et al. STAT4 associates with SLE through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2008. [Epub ahead of print]
37. Nikolov NP, Illei G. Pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 2009 (in press).
38. Lovgren T, Eloranta ML, Kastner B, et al. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006; 54:1917-1927. (Pubitemid 43877941)
39. Stohl W, Xu D, Kim KS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52:2080-2091. (Pubitemid 40994331)
40. Ronnblom L, Alm GV, Eloranta ML. Type I interferon and lupus. Curr Opin Rheumatol (in press).
41. Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37:3582-3586.
42. Perl A, Gergely P Jr, Nagy G, et al. Mitochondrial hyperpolarization: a checkpoint of T cell life, death, and autoimmunity. Trends Immunol 2004; 25:360-367. (Pubitemid 38780952)
43. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-{kappa}B pathway. Int Immunol 2000; 12:1539-1546. (Pubitemid 30838184)
44. Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205:3007-3018.
45. Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19:225-234. (Pubitemid 37011337)
46. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases [review]. Immunity 2006; 25:383-392. (Pubitemid 44354221)
47. Perl A, Fernandez D, Telarico T, et al. T- and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol (in press).
48. Fernandez D, Bonilla E, Mirza N, Perl A. Rapamycin reduces disease activity and normalizes T-cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2983-2988. (Pubitemid 44497779)
49. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008; 205:565-574. An original article documenting the role of mTOR in expression of Foxp3, a transcription factor required for differentiation of Tregs.
50. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008; 105:7797-7802. An original article, documenting the role of mTOR in expression of Foxp3, a transcription factor required for differentiation of Tregs. (Pubitemid 351872718)
51. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579-2588.
52. Hahn BH, Anderson M, Le E, La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58:2488-2497.
53. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324-337.
54. Warner LM, Adams LM, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 1994; 37:289-297.
55. Weinberg JB, Granger DL, Pisetsky DS, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994; 179:651-660. (Pubitemid 24979053)
56. Bahjat FR, Pine PR, Reitsma A, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008; 58:1433-1444. (Pubitemid 351705932)
57. Coca A, Sanz I. B cell depletion in lupus and Sjogren's syndrome: an update. Curr Opin Rheumatol (in press).
58. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748-755. (Pubitemid 351951516)
59. Mevorach D, Elchalal U, Rein AJJT. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies; detection and treatment of first degree atrioventricular block. Curr Opin Rheumatol (in press).
60. Wu T, Qin X, Kurepa Z, et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007; 117:2186-2196. (Pubitemid 47219563)
61. Gergely PJ, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:175-190. (Pubitemid 34121663)
62. Ramanujam M, Wang X, Huang W, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173:3524-3534. (Pubitemid 39142063)
63. Ponce R. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol Pathol 2009; 37:89-99.
64. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Exp Opin Biol Ther 2008; 8:1805-1814.
65. Roll P, Tony HP. B cell-targeted therapies in the treatment of autoimmune diseases. Z Rheumatol 2009; 68:255-259.
66. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study [abstract #L15]. American College of Rheumatology Annual Meeting; 2008.
67. Mihara M, Ohsugi Y, Kishimoto T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by antiinterluekin-6 receptor antibody. Biofactors 2009; 35:47-51.
68. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ betainducible genes and downstream effect in a phase I trial of an antiinterferonalpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1785-1796.